Abnormal serum free light chain ratio predicts poor overall survival in mantle cell lymphoma

British Journal of Haematology

Volumn 160, Issue 1, 2013, Pages 63-69

  Furtado, Michelle ^a   Shah, Nimish ^a   Levoguer, Alison ^b   Harding, Stephen ^b   Rule, Simon ^a  

^a DERRIFORD HOSPITAL   (United Kingdom)

^b Binding Site Group Ltd   (United Kingdom)

Author keywords

Biomarker; Lenalidomide; Mantle cell lymphoma; Overall survival; Serum free light chains

Indexed keywords

IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; LENALIDOMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; HEMATOLOGICAL PARAMETERS; HUMAN; MANTLE CELL LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT CANCER; RETROSPECTIVE STUDY; SERUM FREE LIGHT CHAIN RATIO; SURVIVAL TIME; TREATMENT DURATION;

ADULT; AGED; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; THALIDOMIDE; TUMOR MARKERS, BIOLOGICAL;

EID: 84870827858     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12094     Document Type: Article

References (26)

1. Bird, J., Behrens, J., Westin, J., Turesson, I., Drayson, M., Beetham, R., D'Sa, S., Soutar, R., Waage, A., Gulbrandsen, N., Gregersen, H. & Low, E. (2009) UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). British Journal of Haematology, 147, 22-42.
2. Bird, J., Owen, R., D'Sa, S., Snowden, J., Pratt, G., Littlewood, T., Ashcroft, J., Yong, K., Cook, G., Feyler, S., Davies, F., Morgen, G., Cavenagh, J., Low, E. & Behrens, J. (2010) Guidelines on the diagnosis and management of multiple myeloma. British Journal of Haematology, 152, 32-75.
3. Bradwell, A.R., Carr-Smith, H.D., Mead, G.P., Tang, L.X., Showell, P.J., Drayson, M.T. & Drew, R. (2001) Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clinical Chemistry, 47, 673-680.
4. Dingli, D., Kyle, R.A., Rajkumar, S.V., Nowakowski, G.S., Larson, D.R., Bida, J.P., Gertz, M.A., Therneau, T.M., Melton, L.J., Dispenzieri, A. & Katzmann, J.A. (2006) Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood, 108, 1979-1983.
5. Dispenzieri, A., Lacy, M.Q., Katzmann, J.A., Rajkumar, S.V., Abraham, R.S., Hayman, S.R., Kumar, S.K., Clark, R., Kyle, R.A., Litzow, M.R., Inwards, D.J., Ansell, S.M., Micallef, I.M., Porrata, L.F., Elliott, M.A., Johnston, P.B., Greipp, P.R., Witzig, T.E., Zeldenrust, S.R., Russell, S.J., Gastineau, D. & Gertz, M.A. (2006) Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood, 107, 3378-3383.
6. Dispenzieri, A., Kyle, R.A., Katzmann, J.A., Therneau, T.M., Larson, D., Benson, J., Clark, R.J., Melton, L.J., Gertz, M.A., Kumar, S.K., Fonseca, R., Jelinek, D.F. & Rajkumar, S.V. (2008) Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood, 111, 785-789.
7. Dispenzieri, A., Kyle, R., Merlini, G., Miguel, J.S., Ludwig, H., Hajek, R., Palumbo, A., Jagannath, S., Blade, J., Lonial, S., Dimopoulos, M., Comenzo, R., Einsele, H., Barlogie, B., Anderson, K., Gertz, M., Harousseau, J.L., Attal, M., Tosi, P., Sonneveld, P., Boccadoro, M., Morgan, G., Richardson, P., Sezer, O., Mateos, M V., Cavo, M., Joshua, D., Turesson, I., Chen, W., Shimizu, K., Powles, R., Rajkumar, S V. & Durie, B G M (2009) International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia, 23, 215-224.
8. Drayson, M., Tang, L.X., Drew, R., Mead, G.P., Carr-Smith, H.D. & Bradwell, A.R. (2001) Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood, 97, 2900-2902.
9. Drayson, M., Begum, G., Basu, S., Makkuni, S., Dunn, J., Barth, N. & Child, J.A. (2006) Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood, 108, 2013-2019.
10. Filippi, R.D., Laccarino, G., Frigeri, F., Francia, R.D., Amoroso, B., Marchei, A. & Pinto, A. (2008) The presence of serum free-immunoglobulin light chains and abnormal κ/λ ratios is a frequent finding in patients with Hodgkin's and B-cell non-Hodgkin's lymphoma. Hematology Meeting Reports 2, 2, 18a.
11. Itzykson, R., Le Garff-Tavernier, M., Katsahian, S., Diemert, M.-C., Musset, L. & Leblond, V. (2008) Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom's macroglobulinemia. Haematologica, 93, 793-794.
12. Kang, S.-Y., Suh, J.-T., Lee, H.-J., Yoon, H.-J. & Lee, W.-I. (2005) Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma. Annals of Hematology, 84, 588-593.
13. Katzmann, J.A., Clark, R.J., Abraham, R.S., Bryant, S., Lymp, J.F., Bradwell, A.R. & Kyle, R.A. (2002) Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clinical Chemistry, 48, 1437-1444.
14. Keren, D.F. (1999) Procedures for the evaluation of Monoclonal Immunoglobulins. Archives of Pathology and Laboratory Medicine, 123, 126-132.
15. Kyrtsonis, M.-C., Vassilakopoulos, T.P., Kafasi, N., Sachanas, S., Tzenou, T., Papadogiannis, A., Galanis, Z., Kalpadakis, C., Dimou, M., Kyriakou, E., Angelopoulou, M.K., Dimopoulou, M.N., Siakantaris, M.P., Dimitriadou, E.M., Kokoris, S.I., Panayiotidis, P. & Pangalis, G. A. (2007) Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. British Journal of Haematology, 137, 240-243.
16. Landgren, O., Goedert, J.J., Rabkin, C.S., Wilson, W.H., Dunleavy, K., Kyle, R.A., Katzmann, J.A., Rajkumar, S.V. & Engels, E.A. (2010) Circulating serum free light chains as predictive markers of AIDS-related lymphoma. Journal of Clinical Oncology, 28, 773-779.
17. Martin, W., Abraham, R., Shanafelt, T., Clark, R.J., Bone, N., Geyer, S.M., Katzmann, J. A., Bradwell, A., Kay, N.E. & Witzig, T.E. (2007) Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Translational Research, 149, 231-235.
18. Maurer, M.J., Micallef, I.N.M., Cerhan, J.R., Katzmann, J.A., Link, B.K., Colgan, J.P., Habermann, T.M., Inwards, D.J., Markovic, S.N., Ansell, S.M., Porrata, L.F., Johnston, P.B., Nowakowski, G.S., Thompson, C.A., Gupta, M., Syrbu, S.I., Kurtin, P.J., Macon, W.R., Nikcevich, D.A. & Witzig, T.E. (2011a) Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large b-cell lymphoma. Journal of Clinical Oncology, 29, 1620-1626.
19. Maurer, M.J., Cerhan, J.R., Katzmann, J.A., Link, B.K., Allmer, C., Zent, C.S., Call, T.G., Rabe, K.G., Hanson, C.A., Kay, N.E., Slager, S.L., Witzig, T.E. & Shanafelt, T.D. (2011b) Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. Blood, 118, 2821-2826.
20. Pérez-Galán, P., Mora-Jensen, H., Weniger, M.A., Shaffer, A.L., Rizzatti, E.G., Chapman, C.M., Mo, C.C., Stennett, L.S., Rader, C., Liu, P., Raghavachari, N., Stetler-Stevenson, M., Yuan, C., Pittaluga, S., Maric, I., Dunleavy, K.M., Wilson, W.H., Staudt, L.M. & Wiestner, A. (2011) Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood, 117, 542-552.
21. Pinto, A., De Filippi, R., Iaccarino, G., Di Francia, R., Distinto, M., Frigeri, F., Russo, F., Marchei, A. & Amoroso, B. (2008) Abnormalities in serum free-immunoglobulin light chains show a high and differential frequency among who subtypes of b-cell non-hodgkin's lymphoma (nhl) and may turn of value for therapeutic monitoring: a study of 354 newly diagnosed patients. Blood, 112, 2813.
22. Pinto, A., Iaccarino, G., Russo, F., Amoroso, B., Morelli, E., Riemma, C. & De Filippi, R. (2010) Clinical and biological relevance of serum free light chains (sFLC) assessment in patients with Hodgkin's lymphoma. Hematology Reports, 2, p15.
23. Pratt, G., Harding, S., Holder, R., Fegan, C., Pepper, C., Oscier, D., Gardiner, A., Bradwell, A.R. & Mead, G. (2009) Abnormal serum free light chain ratios are associated with poor survival and may reflect biological subgroups in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 144, 217-222.
24. Pratt, G., Young, P., Levoguer, A., Pepper, C., Fegan, C., Oscier, D., Mead, G. & Harding, S. (2011) Prognostic value of elevated polyclonal serumfree light chains in Stage A chronic lymphocytic leukaemia patients. Annals of Oncology, 22, abstr 260.
25. Swerdlow, S., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (2008) WHO classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. International Agency for Research on Cancer (IARC), Lyon, France.
26. Yegin, Z.A., Ozkurt, Z.N. & Yaǧci, M. (2010) Free light chain: a novel predictor of adverse outcome in chronic lymphocytic leukemia. European Journal of Haematology, 84, 406-411.